Equities research analysts forecast that Insulet Co. (NASDAQ:PODD) will report $125.25 million in sales for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Insulet’s earnings, with estimates ranging from $124.20 million to $127.49 million. Insulet reported sales of $103.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.9%. The business is expected to announce its next earnings results after the market closes on Wednesday, February 21st.
On average, analysts expect that Insulet will report full-year sales of $125.25 million for the current fiscal year, with estimates ranging from $457.40 million to $460.79 million. For the next year, analysts anticipate that the business will report sales of $556.15 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Insulet.
Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.05) EPS.
Insulet (NASDAQ PODD) traded down $0.72 on Friday, reaching $76.53. 295,036 shares of the company’s stock were exchanged, compared to its average volume of 562,354. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The stock has a market cap of $4,542.14, a P/E ratio of -153.06 and a beta of 1.58. Insulet has a 1 year low of $38.43 and a 1 year high of $78.65.
In related news, Director James C. Mullen purchased 2,500 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were bought at an average cost of $67.45 per share, with a total value of $168,625.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Frontier Capital Management Co. LLC lifted its holdings in Insulet by 42.4% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock valued at $144,633,000 after purchasing an additional 624,465 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Insulet during the third quarter valued at about $33,373,000. Janus Henderson Group PLC purchased a new stake in Insulet during the second quarter valued at about $27,428,000. JPMorgan Chase & Co. lifted its holdings in Insulet by 104.9% during the third quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock valued at $34,035,000 after purchasing an additional 313,093 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its holdings in Insulet by 29.6% during the second quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock valued at $43,013,000 after purchasing an additional 191,217 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: This report was reported by Week Herald and is owned by of Week Herald. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2018/02/15/insulet-co-podd-expected-to-announce-quarterly-sales-of-125-25-million.html.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.